ライフサイエンスコーパス: behavioral symptom

1 rhaps before the first clinically noticeable behavioral symptoms.

2 changes in CSF and plasma MT, CSF MHPG, and behavioral symptoms.

3 months, heterozygous female mice also showed behavioral symptoms.

4 dents with AD who exhibited psychotic and/or behavioral symptoms.

5 rrelates the timing of these events with the behavioral symptoms.

6 sociation of ischemic lesions to distinctive behavioral symptoms.

7 working memory impairment and development of behavioral symptoms.

8 me as well as neural correlates of cognitive-behavioral symptoms.

9 report prominent neurological, medical, and behavioral symptoms.

10 significant clinical importance in terms of behavioral symptoms.

11 bnormalities can also treat neurological and behavioral symptoms.

12 suring the severity of several affective and behavioral symptoms.

13 Fmr1 KO mice may also ameliorate autism-like behavioral symptoms.

14 approximately correlating with the onset of behavioral symptoms.

15 therapies to ameliorate core amygdala-based behavioral symptoms.

16 ine for 4weeks from birth can alleviate some behavioral symptoms.

17 tism spectrum disorder prior to emergence of behavioral symptoms.

18 argely ignore biological factors in favor of behavioral symptoms.

19 n (i.e., c-Fos expression) coincide with the behavioral symptoms.

20 related to the development of early autistic behavioral symptoms.

21 isease may lead to recovery of cognitive and behavioral symptoms.

22 ptake inhibitors (SSRIs) in treating certain behavioral symptoms.

23 soluble and insoluble forms of Abeta to the behavioral symptoms and biochemical consequences of the

24 address the neural circuitry underlying the behavioral symptoms and comorbidities, the cell types pl

25 ed on an actual case, we characterize common behavioral symptoms and describe a strategy for selectin

26 neurobiological conditions with overlapping behavioral symptoms and of unknown etiologies.

27 ventions aimed at preventing or ameliorating behavioral symptoms and optimizing developmental outcome

28 Surprisingly, both the onset of home-cage behavioral symptoms and pathological alterations occurre

29 institution was evaluated by comparing their behavioral symptoms and performance on cognitive measure

30 a care had significant effects on decreasing behavioral symptoms and psychotropic medication use in d

31 Behavioral symptoms and semantic dementia were associate

32 ce as evidence emerges of sex differences in behavioral symptoms and treatment response in neuropsych

33 range, 0-176; higher scores indicate greater behavioral symptoms), and functional (Total Functional C

34 n a CBA x C57BL/6 background and show robust behavioral symptoms, and HD knock-in (KI) mice, which ha

35 ted ADHD symptoms, co-occurring emotional or behavioral symptoms, and interpersonal functioning.

36 escribed that precedes the onset of clinical behavioral symptoms, and is brief and age-delimited to t

37 ority of executive function tests, increased behavioral symptoms, and left prefrontal cortex atrophy

38 ce unique challenges due to its early onset, behavioral symptoms, and slow progression of decline.

39 Many psychiatric conditions present complex behavioral symptoms, and the type and magnitude of under

40 Behavioral symptoms are a common adverse effect of breas

41 sociated with diverse neurodevelopmental and behavioral symptoms as well as obesity.

42 owever, their combination resulted in severe behavioral symptoms, as well as spontaneous recurrent co

43 ansmission to the amygdala may contribute to behavioral symptoms associated with depression.

44 Here we use adult zebrafish to study behavioral symptoms associated with drug-evoked seizures

45 rstanding and treatment of the cognitive and behavioral symptoms associated with neurological disorde

46 use embryonic stem cells exhibit none of the behavioral symptoms associated with the Lesch-Nyhan synd

47 ased significantly in transgenics when overt behavioral symptoms began (5-7 weeks) and was most prono

48 strategy that facilitates early treatment of behavioral symptoms by identifying underlying causes and

49 rons could be a useful strategy for treating behavioral symptoms caused by PE.

50 rats significantly ameliorated parkinsonian behavioral symptoms compared with controls (vehicle, sin

51 income supplements, prevalence of adolescent behavioral symptoms decreased significantly.

52 l impairments that predispose the patient to behavioral symptoms, destroy intellectual capacity and p

53 The biological mechanisms underlying behavioral symptom development are poorly understood.

54 ch decrement could contribute to some of the behavioral symptoms displayed by AD patients.

55 Physical and behavioral symptoms displayed by Ndufs4(fky/fky) mice in

56 in function in the first year of life, overt behavioral symptoms do not emerge until the second year.

57 o-basal ganglia circuits underlying discrete behavioral symptom domains relevant to these complex dis

58 Subthreshold behavioral symptoms (e.g., cognitive deficits and substa

59 Psychiatric and behavioral symptoms, functioning, cognition, care needs,

60 Aggressive behavior is a frequent behavioral symptom in Alzheimer's disease.

61 rove cognition and treat psychosis and other behavioral symptoms in Alzheimer's disease, Parkinson's

62 ches to manipulate new neurons show that the behavioral symptoms in animal models of neuropsychiatric

63 This study confirms high rates of behavioral symptoms in breast cancer survivors, particul

64 Importance: Emotional and behavioral symptoms in cognitively normal older people m

65 Nonpharmacologic management of behavioral symptoms in dementia can significantly improv

66 The late afternoon/evening exacerbation of behavioral symptoms in dementia has been recognized by c

67 Systematic screening for behavioral symptoms in dementia is an important preventi

68 n replicate a broad spectrum of parkinsonian behavioral symptoms in Drosophila that are associated wi

69 tial probiotic therapy for GI and particular behavioral symptoms in human neurodevelopmental disorder

70 This may contribute to behavioral symptoms in NBIA and hemochromatosis and is r

71 f atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease

72 Clinical evidence suggests that mood and behavioral symptoms in premenstrual dysphoric disorder (

73 neuronal damage as early as day 10 (prior to behavioral symptoms) in all MOG-injected groups, ii) a s

74 Behavioral symptoms included hyperkinetic behavior (100%

75 Addiction is a disorder of behavioral symptoms including enhanced incentive salienc

76 transtympanic administration of TTX produced behavioral symptoms indicative of transient vestibular d

77 sticity are responsible for the long-lasting behavioral symptoms induced by this form of stress.

78 Although striking behavioral symptoms may be present, care providers often

79 y before the onset of clear neurological and behavioral symptoms, might prevent or ameliorate the dev

80 opsychiatric diseases and are among the many behavioral symptoms not amenable to pharmacological inte

81 of the biochemical, neurophysiological, and behavioral symptoms observed in the fragile X mouse.

82 s a neuropsychiatric syndrome with motor and behavioral symptoms occurring in patients with or withou

83 The behavioral symptoms of AD correlate with the accumulatio

84 stics seen in SHRs that seem to parallel the behavioral symptoms of ADHD are not solely due to hypera

85 owning" is the occurrence or exacerbation of behavioral symptoms of Alzheimer's disease in the aftern

86 trates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy.

87 caused by these individual mutations to core behavioral symptoms of ASD remain poorly understood.

88 c connectivity correlated significantly with behavioral symptoms of ASD.

89 ative to the group curve are associated with behavioral symptoms of ASD.

90 <.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).

91 and brain circuits associated with the core behavioral symptoms of autism.

92 rior to supportive psychotherapy in reducing behavioral symptoms of bulimia nervosa (binge eating and

93 The use of antipsychotics to treat the behavioral symptoms of dementia is associated with great

94 ntrast to 100% of the MOG+Vehicle group with behavioral symptoms of EAE, 63% and 68% of the MOG+OGF a

95 th staff members, showed significantly fewer behavioral symptoms of emotional distress than orphans w

96 networks that may underlie the cognitive and behavioral symptoms of FXS.

97 The mortality rate and the behavioral symptoms of hypertensive encephalopathy decre

98 Our results indicate that the behavioral symptoms of neuropathic pain states can be tr

99 is specifically manifest after the onset of behavioral symptoms of prion disease.

100 la abnormalities contribute to emotional and behavioral symptoms of psychopathy.

101 To the ill patient with diabetes, the behavioral symptoms of sickness such as fatigue and apat

102 nic receptor antagonist mecamylamine induced behavioral symptoms of withdrawal measured as increased

103 tympanic administration of 3 mM TTX produced behavioral symptoms paralleling those previously reporte

104 factors (fear, anxious-misery, psychosis and behavioral symptoms) plus a general factor: overall psyc

105 of 4 stages of thiamine deficiency based on behavioral symptoms: pre-symptomatic stage, ataxic stage

106 Behavioral symptoms preceded neuropathological anomalies

107 ing somatic, cognitive, and psychological or behavioral symptoms, referred to as persistent postconcu

108 Addiction manifests as physiologic and behavioral symptoms related to a maladaptive pattern of

109 use ablation of mGluR7 leads to a variety of behavioral symptoms related to PFC dysfunction, such as

110 For global behavioral symptom scores associated with dementia in el

111 to the NMDA receptor (NMDAR) and results in behavioral symptoms similar to those obtained with model

112 Behavioral symptoms such as aggression were frequently a

113 Behavioral symptoms such as repetitive speech, wandering

114 aptic plasticity in the VP mediates opposing behavioral symptoms; targeting the VP may provide novel

115 vant traits that are more tractable than the behavioral symptoms that classify mental illness.

116 Although primarily defined in terms of behavioral symptoms, the global neurophysiological effec

117 acy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Moo

118 left dorsolateral prefrontal cortex, whereas behavioral symptoms were associated with hypoactivation

119 The behavioral symptoms were evaluated with the Swanson, Nol

120 Behavioral symptoms were evident as early as 15 min post

121 Mood and behavioral symptoms were monitored with daily self-ratin

122 This peptide does not elicit gross behavioral symptoms when injected centrally or periphera

123 wed a unique sex difference in showing these behavioral symptoms, which is reminiscent of human condi

124 ays showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion